Neurological
Refine Search
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November meeting, notable among which was a reversal of a previous rejection of Alzheimer’s drug Leqembi (lecanemab). 15 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Biotechnology
Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released positive interim safety and immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056. 14 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain. 14 November 2024
Pharmaceutical
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
Johnson & Johnson’s subsidiary Janssen has presented further findings on its approved depression drug Spravato (esketamine). 24 November 2022
Pharmaceutical
German family-owned drugmaker Grünenthal today announced that Janneke van der Kamp will join the company as the new chief commercial officer (CCO), effective March 1, 2023. 22 November 2022
Pharmaceutical
Pharma observers of today might sometimes see Merck KGaA as somewhat smaller than its American namesake and as having been left behind by more recent arrivals on the European pharma scene. 21 November 2022
Pharmaceutical
Ireland-headquartered Avadel Pharmaceuticals saw its shares gain more than 12% to $8.03 on Friday, after it announced a positive patent dispute ruling. 21 November 2022
Biotechnology
Among regulatory developments last week, the UK’s AstraZeneca received approval from the US food and Drug Administration (FDA) for its checkpoint inhibitor Imfinzi plus Imjudo for the treatment of lung cancer. Adding to the litany of failures in the search for an effective Alzheimer’s treatment, Swiss giant Roche last Monday released new clinical trial data on its candidate gantenerumab which did not meet the primary endpoint of the study. On the deal-making front, US companies POINT Biopharma and Lantheus Holdings entered into a licensing agreement for PNT2002 and PNT2003, two novel radiopharmaceuticals for cancer. US biotech Arcutis Biotherapies last Wednesday released positive Phase III results for its investigational atopic dermatitis drug roflumilast. 20 November 2022
Biotechnology
Amyloidosis-focused biopharma Attralus and Ossianix, an antibody engineering company developing a single domain antibody platform (VNARs) to deliver molecules across the blood-brain barrier (BBB), have agreed a deal. 18 November 2022
Pharmaceutical
Due to the high-risk nature of drugs being developed for neurology diseases, most product launches in the recent history of Parkinson’s disease have been the result of strategic partnerships for marketing and sales, with few exceptions. 16 November 2022
Biotechnology
Marking a second M&A deal this year, USA-based gene therapy company Kriya Therapeutics today announced the acquisition of a privately held biotechnology company Redpin Therapeutics, which is developing regulatable gene therapies for intractable diseases of the nervous system. 16 November 2022
Biotechnology
Swiss biotech Idorsia has entered into an exclusive licensing agreement with China’s Simcere Pharmaceutical for the commercialization of its dual orexin receptor antagonist daridorexant, a treatment for adult patients with insomnia, in China. 16 November 2022
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday issued a Federal Register notice, Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use, that may help facilitate the development and approval of certain non-prescription naloxone drug products, including through the switch of certain naloxone drug products from prescription status to non-prescription status. 16 November 2022
Biotechnology
Boston, USA-based biotech start-up Jnana Therapeutics, which is leveraging its next-gen chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced two important milestones for the company. 15 November 2022
Pharmaceutical
Clinical-stage biopharma company Satsuma Pharmaceuticals on Monday revealed that its experimental lead treatment for acute migraine headaches failed to meet the main goals of a late-stage trial, sending its shares plunging 83% to $0.68. 15 November 2022
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical and Poland’s Captor Therapeutics, a specialist in the development of targeted protein degradation (TPD)-based drugs, have entered a worldwide drug discovery collaboration. 15 November 2022
Pharmaceutical
California, USA-based Opiant Pharmaceuticals saw its shares skyrocket 111.6% to $20.10 by close of trading yesterday, as it announced a definitive agreement to be acquired by UK drugmaker Indivior. 15 November 2022
Biotechnology
Swiss pharma giant Roche was trading nearly 4% lower early Monday afternoon. 14 November 2022
Pharmaceutical
Following a four to zero vote for the action, the US Federal Trade Commission (FTC) has filed an amicus brief with the US District Court for the District of Delaware in the case of US drugmaker Jazz Pharmaceuticals versus Ireland-incorporated Avadel Pharmaceuticals 12 November 2022
Pharmaceutical
German drugmaker Merck KGaA has reported net sales in the 2022 third quarter of 5.8 billion euros ($5.8 billion), in line with many analysts’ expectations, with earnings per share coming in at 2.68 euros. 10 November 2022
Pharmaceutical
Denmark-based CNS specialist Lundbeck saw its shares rise nearly 4% to 28.48 Danish kroner in early trading, after the company released financial results for the first nine months of 2022. 9 November 2022
Biotechnology
VectorY Therapeutics, a Dutch biotech developing vectorized antibody approaches for neurodegenerative diseases, has named Sander van Deventer, co-founder and formerly chief technology officer, as chief executive. 8 November 2022
Generics
New York Attorney General Letitia James last Friday marked a major milestone in her fight against the opioid crisis in New York state, when she announced that her office has secured up to $523 million from the US subsidiary and affiliates of Israeli generics giant Teva Pharmaceutical Industries for their role in fueling the opioid crisis. 7 November 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze